H5N1 Updates

- Cambodia reported its fourth human H5N1 case of 2026, a 66‑year‑old woman who tested positive on April 21. ( ) - Moderna has begun a Phase 3 trial of its mRNA H5N1 vaccine candidate mRNA‑1018, targeting about 4,000 adult participants. ( ) - Health reports say the virus is evolving and spreading, but current sustained human-to-human transmission risk remains considered low. ( )

Bird flu is still infecting people in scattered cases — and health officials say the virus is spreading in animals while sustained person-to-person spread remains low. (who.int) Cambodia reported a new human H5N1 infection on April 22: a 66-year-old woman from Trapaing Thkov village in Romduol district, Svay Rieng province, who tested positive on April 21. She was hospitalized in isolation after investigators found sick and dead chickens in her village earlier in April. (kampucheathmey.com) (bnonews.com) Cambodian health teams said some dead poultry had been handled for cooking, and response workers were tracing contacts, giving antiviral medicine, and running local risk-awareness campaigns. The case was Cambodia’s fourth confirmed human H5N1 infection of 2026. (kampucheathmey.com) (cambodianess.com) H5N1 is an avian influenza virus, or bird flu virus, that mainly circulates in birds but can jump into mammals and, in rare cases, people. The current global concern is less about one isolated patient than about the virus persisting across poultry, wild birds, and a growing list of mammals. (cdc.gov) (paho.org) The United States Centers for Disease Control and Prevention says H5 bird flu is widespread in wild birds and has caused outbreaks in poultry and U.S. dairy cows, with sporadic human cases tied mostly to animal exposure. The agency says the current public health risk remains low and it has not identified sustained human-to-human transmission. (cdc.gov 1) (cdc.gov 2) The World Health Organization, the Food and Agriculture Organization, and the World Organisation for Animal Health reached a similar conclusion in their latest joint assessment, calling the global public health risk from influenza A(H5) viruses low. They said risk for people with occupational exposure can rise to low-to-moderate depending on local outbreaks and protective measures. (who.int) At the same time, Moderna said this week it has started a Phase 3 trial of its H5 pandemic influenza vaccine candidate, mRNA-1018. The study is expected to enroll about 4,000 adults age 18 and older in the United States and United Kingdom to measure safety and immune response. (newswire.com) (stocktitan.net) Messenger RNA vaccines work by giving the body genetic instructions to make a harmless piece of a virus, training the immune system before a real exposure. Moderna said the H5 program is backed by funding from the Coalition for Epidemic Preparedness Innovations, which committed up to $54.3 million in December 2025 to support late-stage development. (newswire.com) (stocktitan.net) Public health agencies are treating the two tracks — scattered human infections and vaccine preparation — as part of the same problem. The virus is still behaving mostly like an animal outbreak, but governments and drugmakers are building tools in case that changes. (who.int) (cdc.gov) (newswire.com)

Get your own daily briefing

Scout delivers personalized news, insights, and conversations tailored to your role and industry.

Download on the App Store

Shared from Scout - Be the smartest in the room.